Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.38 |
| ▸ | ACACB | O00763 | 4/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | JUN | P05412 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333319 | 1.00 | CDK4 (0.38) | CDK4GSK3BHSD11B1ACACBGRM5 | |
| SCHEMBL1333321 | 1.00 | CDK4 (0.38) | CDK4GSK3BHSD11B1ACACBGRM5 | |
| SCHEMBL1333323 | 1.00 | CDK4 (0.38) | CDK4GSK3BHSD11B1ACACBGRM5 | |
| SCHEMBL1334469 | 1.00 | CDK4 (0.38) | CDK4GSK3BHSD11B1ACACBGRM5 | |
| SCHEMBL1333993 | 0.90 | GRM5 (0.39) | HSD11B1ACACBGRM5MAPK8MAPK9 | |
| SCHEMBL1333997 | 0.90 | GRM5 (0.39) | HSD11B1ACACBGRM5MAPK8MAPK9 | |
| SCHEMBL1333991 | 0.90 | GRM5 (0.39) | HSD11B1ACACBGRM5MAPK8MAPK9 | |
| SCHEMBL1032650 | 0.89 | MAPK1 (0.39) | CDK4GSK3BHSD11B1ACACBGRM5 | |
| SCHEMBL1332253 | 0.89 | MAPK1 (0.39) | CDK4GSK3BHSD11B1ACACBGRM5 | |
| SCHEMBL12125243 | 0.89 | MAPK1 (0.39) | CDK4GSK3BHSD11B1ACACBGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513242-B2 | Pyrimidine compounds and methods of making and using same | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CYSTIC FIBROSIS FOUNDATION | 2011-11-17 | — | — | US | disclosed |
| WO-2010068863-A2 | PYRIMIDINE COMPOUNDS AND METHODS OF MAKING AND USING SAME | CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281873-A1 | Pyrimidine Compounds and Methods of Making and Using Same | CFTR, GPR17, TYMS | CDK4 2340/4885GSK3B 4700/4885HSD11B1 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.